Summit Trail Advisors LLC Sells 946 Shares of Danaher Co. (NYSE:DHR)

Summit Trail Advisors LLC decreased its stake in shares of Danaher Co. (NYSE:DHR) by 9.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,734 shares of the conglomerate’s stock after selling 946 shares during the quarter. Summit Trail Advisors LLC’s holdings in Danaher were worth $2,023,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Banco Santander S.A. purchased a new position in Danaher during the 3rd quarter valued at about $683,000. First Citizens Bank & Trust Co. increased its holdings in Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after buying an additional 149 shares during the period. Cercano Management LLC raised its stake in Danaher by 11.4% in the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after buying an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after acquiring an additional 96,395 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Danaher by 4.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after acquiring an additional 142 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR traded down $0.98 during mid-day trading on Monday, reaching $247.40. The company had a trading volume of 1,593,955 shares, compared to its average volume of 2,755,556. The stock has a 50 day moving average of $248.48 and a two-hundred day moving average of $232.60. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $183.25 billion, a P/E ratio of 41.93, a PEG ratio of 3.82 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the firm earned $2.36 EPS. The business’s quarterly revenue was down 2.6% on a year-over-year basis. On average, analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Citigroup raised their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Royal Bank of Canada lifted their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Raymond James boosted their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Insiders Place Their Bets

In other news, Director Teri List sold 3,289 shares of Danaher stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 107,273 shares of company stock worth $26,813,819. 10.90% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.